|
1
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics. 2012. CA
Cancer J Clin. 65:872015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang Y, Shi J, Huang H, Ren J, Li N and
Dai M: Burden of colorectal cancer in China. Zhonghua Liu Xing Bing
Xue Za Zhi. 36:709–714. 2015.(In Chinese). PubMed/NCBI
|
|
4
|
Carrie P: Declines in death from
colorectal cancer in europe deemed major success. Cancer. 124:2876.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Al-Sukhni E and Gallinger S: Treatment of
colorectal cancer. Springer Netherlands. 809–812. 2010.
|
|
6
|
Coppedè F, Lopomo A, Spisni R and Migliore
L: Genetic and epigenetic biomarkers for diagnosis, prognosis and
treatment of colorectal cancer. World J Gastroenterol. 20:943–956.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ciombor KK, Wu C and Goldberg RM: Recent
therapeutic advances in the treatment of colorectal cancer. Annu
Rev Med. 66:83–95. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ju J: miRNAs as biomarkers in colorectal
cancer diagnosis and prognosis. Bioanalysis. 2:901–906. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen X, Shi K, Wang Y, Song M, Zhou W, Tu
H and Lin Z: Clinical value of integrated-signature miRNAs in
colorectal cancer: miRNA expression profiling analysis and
experimental validation. Oncotarget. 6:37544–37556. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang Q, Jie Z, Ye S, Li Z, Han Z, Wu J,
Yang C and Jiang Y: Genetic variations in miR-27a gene decrease
mature miR-27a level and reduce gastric cancer susceptibility.
Oncogene. 33:193–202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M
and Croce CM: Human microRNA genes are frequently located at
fragile sites and genomic regions involved in cancers. Proc Natl
Acad Sci USA. 10:2999–3004. 2004. View Article : Google Scholar
|
|
12
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
43:834–838. 2005. View Article : Google Scholar
|
|
13
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Calin GA and Croce CM: MicroRNA-cancer
connection: The beginning of a new tale. Cancer Res. 66:7390–7394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou L, Liang X, Zhang L, Yang L, Nagao N,
Wu H, Liu C, Lin S, Cai G and Liu J: MiR-27a-3p functions as an
oncogene in gastric cancer by targeting BTG2. Oncotarget.
7:51943–51954. 2016.PubMed/NCBI
|
|
16
|
Liu T, Tang H, Lang Y, Liu M and Li X:
MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by
targeting prohibitin. Cancer Lett. 273:233–242. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu W, Liu M, Peng X, Zhou P, Zhou J, Xu K,
Xu H and Jiang S: miR-24-3p and miR-27a-3p promote cell
proliferation in glioma cells via cooperative regulation of MXI1.
Int J Oncol. 42:757–766. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao N, Sun H, Sun B, Zhu D, Zhao X, Wang
Y, Gu Q, Dong X, Liu F, Zhang Y and Li X: miR-27a-3p suppresses
tumor metastasis and VM by down-regulating VE-cadherin expression
and inhibiting EMT: an essential role for Twist-1 in HCC. Sci Rep.
6:230912016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu XZ, Wang KP, Song HJ, Xia JH, Jiang Y
and Wang YL: MiR-27a-3p promotes esophageal cancer cell
proliferation via F-box and WD repeat domain-containing 7 (FBXW7)
suppression. Int J Clin Exp Med. 8:15556–15562. 2015.PubMed/NCBI
|
|
20
|
Nakata W, Uemura M, Sato M, Fujita K,
Jingushi K, Ueda Y, Kitae K, Tsujikawa K and Nonomura N: Expression
of miR-27a-3p is an independent predictive factor for recurrence in
clear cell renal cell carcinoma. Oncotarget. 6:21645–21654. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li L and Luo Z: Dysregulated miR-27a-3p
promotes nasopharyngeal carcinoma cell proliferation and migration
by targeting Mapk10. Oncol Rep. 37:2679–2687. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Winkler GS: The mammalian
anti-proliferative BTG/Tob protein family. J Cell Physiol.
222:66–72. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sasajima H, Nakagawa K and Yokosawa H:
Antiproliferative proteins of the BTG/Tob family are degraded by
the ubiquitin-proteasome system. Eur J Biochem. 269:3596–3604.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu R, Zou ST, Wan JM, Li W, Li XL and Zhu
W: BTG1 inhibits breast cancer cell growth through induction of
cell cycle arrest and apoptosis. Oncol Rep. 30:2137–2144. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu C, Tao T, Xu B, Lu K, Zhang L, Jiang
L, Chen S, Liu D, Zhang X, Cao N and Chen M: BTG1 potentiates
apoptosis and suppresses proliferation in renal cell carcinoma by
interacting with PRMT1. Oncol Lett. 10:619–624. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
He C, Yu T, Shi Y, Ma C, Yang W, Fang L,
Sun M, Wu W, Xiao F, Guo F, et al: MicroRNA 301A promotes
intestinal inflammation and colitis-associated cancer development
by inhibiting BTG1. Gastroenterology. 152:1434–1448. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee AS, Kranzusch PJ and Cate JH: eIF3
targets cell-proliferation messenger RNAs for translational
activation or repression. Nature. 522:111–114. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Waanders E, Scheijen B, van der Meer LT,
van Reijmersdal SV, van Emst L, Kroeze Y, Sonneveld E, Hoogerbrugge
PM, van Kessel AG, van Leeuwen FN and Kuiper RP: The origin and
nature of tightly clustered BTG1 deletions in precursor B-cell
acute lymphoblastic leukemia support a model of multiclonal
evolution. PLoS Genet. 8:e10025332012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rouault JP, Rimokh R, Tessa C, Paranhos G
Ffrench M, Duret L, Garoccio M, Germain D, Samarut J and Magaud JP:
BTG1, a member of a new family of antiproliferative genes. Embo J.
11:1663–1670. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Corjay MH, Kearney MA, Munzer DA, Diamond
SM and Stoltenborg JK: Antiproliferative gene BTG1 is highly
expressed in apoptotic cells in macrophage-rich areas of advanced
lesions in Watanabe heritable hyperlipidemic rabbit and human. Lab
Invest. 78:47–58. 1998.PubMed/NCBI
|
|
31
|
Nahta R, Yuan LX, Fiterman DJ, Zhang L,
Symmans WF, Ueno NT and Esteva FJ: B cell translocation gene 1
contributes to antisense Bcl-2-mediated apoptosis in breast cancer
cells. Mol Cancer Ther. 5:93–60. 2006. View Article : Google Scholar
|
|
32
|
Li Y, Choi PS, Casey SC, Dill DL and
Felsher DW: MYC through miR-17-92 suppresses specific target genes
to maintain survival, autonomous proliferation, and a neoplastic
state. Cancer Cell. 26:62–72. 2014. View Article : Google Scholar
|
|
33
|
Zheng HC, Li J, Shen DF, Yang XF, Zhao S,
Wu YZ, Takano Y, Sun HZ, Su RJ, Luo JS and Gou WF: BTG1 expression
correlates with pathogenesis, aggressive behaviors and prognosis of
gastric cancer: A potential target for gene therapy. Oncotarget.
19:685–705. 2015.
|
|
34
|
Williams G and Stoeber K: The cell cycle
and cancer. J Pathol. 226:352–364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao S, Chen SR, Yang XF, Shen DF, Takano
Y, Su RJ and Zheng HC: BTG1 might be employed as a biomarker for
carcinogenesis and a target for gene therapy in colorectal cancers.
Oncotarget. 8:7502–7520. 2017.PubMed/NCBI
|
|
36
|
Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin
P, Lu Y, Li Q and Liu J: MiR-139 inhibits invasion and metastasis
of colorectal cancer by targeting the type I insulin-like growth
factor receptor. Biochem Pharmacol. 84:320–330. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zou F, Mao R, Yang L, Lin S, Lei K, Zheng
Y, Ding Y, Zhang P, Cai G, Liang X and Liu J: Targeted deletion of
miR-139-5p activates MAPK, NF-κB and STAT3 signaling and promotes
intestinal inflammation and colorectal cancer. FEBS J.
283:1438–1452. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bai Y, Qiao L, Xie N, Shi Y, Liu N and
Wang J: Expression and prognosis analyses of the Tob/BTG
antiproliferative (APRO) protein family in human cancers. PLoS One.
12:e01849022017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Krek A, Grün D, Poy MN, Wolf R, Rosenberg
L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M
and Rajewsky N: Combinatorial microRNA target predictions. Nat
Genet. 37:495–500. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bandyopadhyay S and Mitra R: TargetMiner:
microRNA target prediction with systematic identification of
tissue-specific negative examples. Bioinformatics. 25:2625–2631.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xu W, San Lucas A, Wang Z and Liu Y:
Identifying microRNA targets in different gene regions. BMC
Bioinformatics. 15 (Suppl 7):S42014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ferrer RR, Ramirez M, Beckman LJ, Danao LL
and Ashing-Giwa KT: The impact of cultural characteristics on
colorectal cancer screening adherence among Filipinos in the United
States: A pilot study. Psychooncology. 20:862–870. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Weitz J, Koch M, Debus J, Höhler T, Galle
PR and Büchler MW: Colorectal cancer. Lancet. 365:1066. 2005.
View Article : Google Scholar
|
|
45
|
Wolpin BM and Mayer RJ: Systemic treatment
of colorectal cancer. Gastroenterology. 134:1296–1310. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhou S, Huang Q, Zheng S, Lin K, You J and
Zhang X: miR-27a regulates the sensitivity of breast cancer cells
to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis. Tumour Biol.
37:6837–6845. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lin-Lin XU, et al: Effects of genistein on
the growth of ovarian cancer cell SKOV3 by regulating miR-27a and
target gene expression. Chin J Clin Pharmacol Ther. 17:1321–1326.
2012.(In Chinese).
|
|
48
|
Ma Y, Yu S, Zhao W, Lu Z and Chen J:
miR-27a regulates the growth, colony formation and migration of
pancreatic cancer cells by targeting Sprouty2. Cancer Lett.
298:150–158. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Choo KB, Soon YL, Nguyen PN, Hiew MS and
Huang CJ: MicroRNA-5p and −3p co-expression and cross-targeting in
colon cancer cells. J Biomed Sci. 21:952014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zeng G, Xun W, Wei K, Yang Y and Shen H:
MicroRNA-27a-3p regulates epithelial to mesenchymal transition via
targeting YAP1 in oral squamous cell carcinoma cells. Oncol Rep.
36:1475–1482. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhao Y, Wang P, Meng J, Ji Y, Xu D, Chen
T, Fan R, Yu X, Yao J and Dong C: MicroRNA-27a-3p inhibits
melanogenesis in mouse skin melanocytes by targeting Wnt3a. Int J
Mol Sci. 16:10921–10933. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Prévôt D, Voeltzel T, Birot AM, Morel AP,
Rostan MC, Magaud JP and Corbo L: The Leukemia-associated Protein
Btg1 and the p53-regulated Protein Btg2 Interact with the
Homeoprotein Hoxb9 and enhance its transcriptional activation. J
Biol Chem. 275:147–153. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Corjay MH, Kearney MA, Munzer DA, Diamond
SM and Stoltenborg JK: Antiproliferative gene BTG1 is highly
expressed in apoptotic cells in macrophage-rich areas of advanced
lesions in Watanabe heritable hyperlipidemic rabbit and human. Lab
Invest. 78:847–858. 1998.PubMed/NCBI
|
|
54
|
Sun G, Liu Q, Cheng Y and Hu W: B cell
translocation gene 1 reduces the biological outcome of kidney
cancer through induction of cell proliferation, cell cycle arrest,
cell apoptosis and cell metastasis. Int J Mol Med. 35:777–8348.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bretones G, Delgado MD and León J: Myc and
cell cycle control. Biochim Biophys Acta. 1849:506–516. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sun GG, Wang YD, Cheng YJ and Hu WN: The
expression of BTG1 is downregulated in nasopharyngeal carcinoma and
possibly associated with tumour metastasis. Mol Biol Rep.
41:5979–5988. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sun GG, Wang YD, Cheng YJ and Hu WN: BTG1
underexpression is an independent prognostic marker in esophageal
squamous cell carcinoma. Tumour Biol. 35:9707–9716. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lu YF, Sun GG, Liu Q, Yang CR and Cheng
YJ: BTG1 expression in thyroid carcinoma: Diagnostic indicator and
prognostic marker. Int J Oncol. 45:1574–1582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Zhao Y, Gou WF, Chen S, Takano Y and Zheng
HC: BTG1 expression correlates with pathogenesis and progression of
ovarian carcinomas. Int J Mol Sci. 14:19670–19680. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Smolewski P and Robak T: Inhibitors of
apoptosis proteins (IAPs) as potential molecular targets for
therapy of hematological malignancies. Curr Mol Med. 11:633–649.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Nicholson DW and Thornberry NA: Trends
Biochem. Sci. 22:299–306. 1997.
|
|
62
|
Salvesin GS and Dixit VM: Caspases:
Intracellular signaling by proteolysis. Cell. 91:443–446. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC,
Hwang JI, Chung CW, Jung YK and Oh BH: An anti apoptotic protein
human survivin is a direct inhibitor of caspase-3 and −7.
Biochemistry. 40:1117–1123. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Nossa CW, Jain P, Tamilselvam B, Gupta VR,
Chen LF, Schreiber V, Desnoyers S and Blanke SR: Activation of the
abundant nuclear factor poly(ADP-ribose) polymerase-1 by
Helicobacter pylori. Proc Natl Acad Sci USA. 106:19998–20003. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Li Y, Zhang Y, Xiao S, Kong P, Cheng C,
Shi R, Wang F, Zhang L, Wang J, Jia Z, et al: Mps1 is associated
with the BRAFV600E mutation but does not rely on the classic
RAS/RAF/MEK/ERK signaling pathway in thyroid carcinoma. Oncol Lett.
15:9978–9986. 2018.PubMed/NCBI
|
|
66
|
Cristea S and Sage J: Is the Canonical
RAF/MEK/ERK signaling pathway a therapeutic target in SCLC? J
Thorac Oncol. 11:1233–1241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhou K, Luo X, Wang Y, Cao D and Sun G:
MicroRNA-30a suppresses tumor progression by blocking
Ras/Raf/MEK/ERK signaling pathway in hepatocellular carcinoma.
Biomed Pharmacother. 93:1025–1032. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Rapp UR, Goldsborough MD, Mark GE, Bonner
TI, Groffen J, Reynolds FH Jr and Stephenson JR: Stephenson
Structure and biological activity of v-raf, a unique oncogene
transduced by a retrovirus Proc. Natl Acad Sci. 80:4218–4222. 1983.
View Article : Google Scholar
|
|
69
|
Montagut C and Settleman J: Targeting the
RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 283:125–134.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Steelman LS, Chappell WH, Abrams SL, Kempf
RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F,
Mazzarino MC, et al: Roles of the Raf/MEK/ERK and
PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity
to therapy-implications for cancer and aging. Aging (Albany NY).
3:192–222. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Zhang H, Tang J, Li C, Kong J, Wang J, Wu
Y, Xu E and Lai M: MiR-22 regulates 5-FU sensitivity by inhibiting
autophagy and promoting apoptosis in colorectal cancer cells.
Cancer Lett. 356:781–790. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Weng W, Liu N, Toiyama Y, Kusunoki M,
Nagasaka T, Fujiwara T, Wei Q, Qin H, Lin H, Ma Y and Goel A: Novel
evidence for a PIWI-interacting RNA (piRNA) as an oncogenic
mediator of disease progression, and a potential prognostic
biomarker in colorectal cancer. Mol Cancer. 17:162018. View Article : Google Scholar : PubMed/NCBI
|
